Scientists Discover Amazing New Benefit of Ozempic: Reducing Alcohol and Opioid Addiction
New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people with substance use disorders. These medications, often prescribed for diabetes and weight issues,
Ozempic (and similar medications) may be the new treatment for opioid and alcohol use disorder
A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.
Ozempic could cut binge drinking and opioid abuse
Ozempic could cut binge drinking and opioid abuse, major research suggests. A US study of more than 800,000 people with a history of alcohol use disorder found those put on the weight-loss jab were half as likely to require hospital treatment as a result of drinking.
Ozempic and similar drugs may lower risks for opioid and alcohol use disorders
A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related conditions appear to have a 40% lower rate of opioid overdose and a 50% lower rate of alcohol intoxication than people with OUD and AUD who do not take Ozempic or similar medications.
Ozempic shows promise for treating alcohol and drug abuse, study finds
The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too.
Ozempic may help battle drug and alcohol addiction
Weight-loss drugs like Ozempic and Mounjaro, which also treat diabetes, may help users battling drug and alcohol abuse as well. A study published in the Addiction medical journal Wednesday showed roughy 1.
Ozempic could help with opioid and alcohol abuse, new research shows
A new study published Thursday found that groundbreaking weight loss and diabetes medications also combat opioid-use disorder and alcohol misuse disorder. This is the second study this fall to suggest that GLP-1s,
Managed Healthcare Executive8h
In the Real World, People Do Not Stick With GLP-1s for Weight Loss | AMCP Nexus 2024
Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...
Bariatric surgery found to be more cost effective than newer weight loss drugs alone
Newer weight loss drugs are cost effective in the long term only when combined with bariatric weight loss surgery, according ...
rheumatologyadvisor11h
Diabetes, High BMI, Previous Metformin Common in Teens With Rx for GLP-1 RAs
Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have comorbid type 2 diabetes, high body mass index, and a previous metformin ...
Stoneham Independent1d
Weight-Loss Meds Like Wegovy Could Battle Alcoholism
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid ...
ahajournals.org7d
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and ...
healthday on MSN3d
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduc ...
Ozempic: Weight Loss Drug May Help With Addiction Too
These medications have been associated with a 40 percent reduction in opioid overdose and 50 percent lower rate of alcohol intoxication.
EurekAlert!2y
Novel Glucagon Like Peptide-1 (GLP-1) Drugs Designed for Type II Diabetes (IMAGE)
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
Response begins enrolment for trial of RDX-002 for weight management
Response Pharmaceuticals has initiated subject enrolment for a Phase II trial of its drug candidate RDX-002, designed to ...